Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Bullboard (CSE:AGN)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Post by SkywalkerofLukeon Apr 14, 2023 4:40pm

Recent News

AGN.c AGNPF continues to be a leader in stroke treatment space (market est. to reach value of $15B by 2027) as they completed the second cohort in its escalating dose Phase 1 clinical study of an ...more  
139
Comment by Whalewatcher1on Apr 14, 2023 10:33am

RE:Promising results from latest update in DMT trials

huh, what;s promising that 2 doses are safe? might want to ask how this will funded . . . 
74
Discussion
Post by XeniaTechieon Apr 13, 2023 1:50pm

Promising results from latest update in DMT trials

Algernon Pharmaceuticals' phase one study of DMT for stroke patients involves escalating doses to understand safety and tolerability. First and second cohort showed promising results with latest ...more  
186
Discussion
Post by SkywalkerofLukeon Apr 11, 2023 2:00pm

Recent News

Did you know 1 in 4 adults older than 25 will experience a stroke in their lifetime - it is a huge and daunting problem that many of us will have to face in our lives. The global stroke treatment ...more  
265
Comment by Bimmaxbroon Apr 10, 2023 2:34pm

RE:AP Loves The Thrill Of The Hunt Way More Than Kill-er Data

In light of current events, your posting of the Elmer Fudd cartoon could be a little concerning. You don't own any guns do you ?
71
Discussion
Comment by C10H12N2on Apr 07, 2023 7:17pm

RE:RE:RE:RE:AP Loves The Thrill Of The Hunt Way More Than Kill-er Data

Names Names Names. That's all you've. Meanwhile, you want someone to play your sily little gsme of hide gthe ball. You go jump through hoops Care Bear to all get to those proclaimed success ...more  
128
Discussion
Comment by TheBearInTheWoodson Apr 07, 2023 4:37pm

RE:RE:RE:RE:RE:AP Loves The Thrill Of The Hunt Way More Than Kill-er Data

I can see your still a pleasure of a human being, with of course no meaningful content.
71
Discussion
Comment by TheBearInTheWoodson Apr 07, 2023 4:34pm

RE:RE:RE:AP Loves The Thrill Of The Hunt Way More Than Kill-er Data

As much as I enjoy you losing your mind, there was a link to an article that showed peptides success rate to approval. Take a deep breath  Clinical Success Rates Page 17 whacko 
73
Discussion
Comment by C10H12N2on Apr 07, 2023 10:58am

RE:RE:AP Loves The Thrill Of The Hunt Way More Than Kill-er Data

As predicted this morning at Arch's message board, you crawled out of a hole to defend your friend Riverfolk. You're a tight knit group of childish and predictablt "adults". You have ...more  
93
Discussion
Comment by TheBearInTheWoodson Apr 07, 2023 9:52am

RE:AP Loves The Thrill Of The Hunt Way More Than Kill-er Data

You were pumping this thing at $58 and you expect anyone to care your current feelings? You have some serious Stockholm syndrome. Are you upset the COVID cheques stopped? 
61
Discussion
Post by Justdosomeddon Apr 06, 2023 1:44pm

Dosing of 2nd Cohort in Phase 1 DMT Clinical Study

There are so many illnesses that still have no effective treatments despite the significant advancements in healthcare over the past century. But, with these developments and new drugs that have been ...more  
142
Post by SkywalkerofLukeon Apr 05, 2023 4:04pm

AGN Completed 2nd Cohort of Phase 1 DMT Study

AGN.c recently announced they completed the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 (DMT). AGNPF is a Canadian clinical stage ...more  
172
Post by bmreedon Apr 05, 2023 12:38pm

News Update: $AGN CEO Chris Moreau - Phase 1 Trial AP-188

News Update: Algernon Pharmaceuticals $AGN w CEO Christopher Moreau - Phase 1 Trial for AP-188 - Doses 2nd Cohort - https://youtu.be/2XM7SC5iQaI   Algernon Pharmaceuticals Inc.'s ...more  
92
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities